NOVOZYMES, GREAT GREEN PLAY BUT WAIT (REDUCE; -9% DOWNSIDE)
20/11/20 -"Novozymes (Reduce, Denmark) is a classic example of a ‘good company at an unattractive price’. We were cautiously optimistic on this Denmark-based enzyme market leader (48% share) when we teased ..."
Pages
51
Language
English
Published on
20/11/20
You may also be interested by these reports :
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients